標題: Titlebook: Controversies in the Management of Gynecological Cancers; Jonathan A. Ledermann,Carien L. Creutzberg,Michael Book 2014 Springer-Verlag Lon [打印本頁] 作者: dabble 時間: 2025-3-21 17:11
書目名稱Controversies in the Management of Gynecological Cancers影響因子(影響力)
書目名稱Controversies in the Management of Gynecological Cancers影響因子(影響力)學科排名
書目名稱Controversies in the Management of Gynecological Cancers網絡公開度
書目名稱Controversies in the Management of Gynecological Cancers網絡公開度學科排名
書目名稱Controversies in the Management of Gynecological Cancers被引頻次
書目名稱Controversies in the Management of Gynecological Cancers被引頻次學科排名
書目名稱Controversies in the Management of Gynecological Cancers年度引用
書目名稱Controversies in the Management of Gynecological Cancers年度引用學科排名
書目名稱Controversies in the Management of Gynecological Cancers讀者反饋
書目名稱Controversies in the Management of Gynecological Cancers讀者反饋學科排名
作者: Lumbar-Stenosis 時間: 2025-3-21 23:38 作者: boisterous 時間: 2025-3-22 04:11 作者: 不利 時間: 2025-3-22 05:49
New Views of Ovarian Carcinoma Types: How Will This Change Practice?,ost clear cell carcinomas). Type II tumors present in advanced stage and appear to progress rapidly (high-grade serous carcinomas). A body of literature is now converging on a consensus that the majority of high-grade serous carcinomas arise from intraepithelial carcinoma of the fallopian tube. Thes作者: INCH 時間: 2025-3-22 08:50
Is Cervix Cancer a Disappearing Disease? Impact of HPV Vaccination in Developed Countries,etween treatment for CIN and obstetric complications is somewhat conflicting. In general terms, the timing and extent of the impact of vaccination on organized screening programs will depend on factors specific to each country, including coverage rates achieved in vaccination programs, the age range作者: 下垂 時間: 2025-3-22 15:31
What Is the Role of Cytotoxic Chemotherapy in Advanced Cervical Cancer?,oxicity and minimal survival benefit to those regimens with improved side effect profile and steady gains in clinical activity. Numerous international trials are under way trying to improve outcomes in this unfortunate patient population. Targeted therapy for cervical cancer remains in its infancy, 作者: 下垂 時間: 2025-3-22 18:26 作者: 同義聯想法 時間: 2025-3-22 22:13 作者: Inflated 時間: 2025-3-23 03:26
What Is the Best Treatment Model for Gynecologic Cancers? Does Centralization Help?,has continued. It is of great importance that EOC be centralized to centers with sufficiently skilled surgeons and the necessary organization to appropriately handle advanced EOC patients. This requires national health systems to secure sufficient education and training for all medical staff involve作者: 過剩 時間: 2025-3-23 08:18
Bowel Obstruction in Ovarian Cancer: To Operate or Not?,troversial. Nonsurgical management includes palliative chemotherapy, stent placement for local obstruction, and palliation of symptoms, in particular vomiting and pain. The main consideration for the choice of treatment should be its effect on quality of life. The key issue, therefore, is optimal se作者: 豎琴 時間: 2025-3-23 09:48 作者: Recess 時間: 2025-3-23 15:13 作者: reperfusion 時間: 2025-3-23 18:37
https://doi.org/10.1007/978-94-009-2717-9etween treatment for CIN and obstetric complications is somewhat conflicting. In general terms, the timing and extent of the impact of vaccination on organized screening programs will depend on factors specific to each country, including coverage rates achieved in vaccination programs, the age range作者: CRP743 時間: 2025-3-23 22:24
R. Belmans,A. Vandenput,W. Geysenoxicity and minimal survival benefit to those regimens with improved side effect profile and steady gains in clinical activity. Numerous international trials are under way trying to improve outcomes in this unfortunate patient population. Targeted therapy for cervical cancer remains in its infancy, 作者: 設想 時間: 2025-3-24 05:22 作者: 亞麻制品 時間: 2025-3-24 08:16 作者: 支柱 時間: 2025-3-24 14:09 作者: paragon 時間: 2025-3-24 18:03 作者: 媒介 時間: 2025-3-24 22:51 作者: Gerontology 時間: 2025-3-25 01:25 作者: 古老 時間: 2025-3-25 05:25
Introduction to Phase-Reference Mapping and controversies including surgical staging and surgical and medical treatments. We provide a critical overview of the most debated and controversial aspects of this challenging disease. In surgery, we focus on confidence in initial staging and the impact of under-assessment and undertreatment, th作者: 不容置疑 時間: 2025-3-25 10:56
Very Long Baseline Interferometryous carcinoma. High-grade serous carcinoma causes the vast majority of ovarian cancer deaths. This classification correlates with a variety of distinctive clinical, epidemiological, molecular, and behavioral features. This cell type-specific approach is a valuable framework for understanding the bio作者: 過于光澤 時間: 2025-3-25 13:50 作者: Vital-Signs 時間: 2025-3-25 16:53
Very Long Baseline Interferometryed, with emphasis on the controversial issues and pro/con discussions. Ongoing issues of debate for which future trials should provide evidence are highlighted. Risk-based treatment selection is emphasized, with the aim of sparing many patients with low-risk endometrial cancer unnecessary toxicities作者: instulate 時間: 2025-3-25 22:45
https://doi.org/10.1007/978-94-009-2717-9to further individualize therapy. Perhaps, hormonal therapy can be seen as the first biological targeted agent followed by anti-VEGF agents and mTOR inhibitors. Chemotherapy continues to be the mainstay in the treatment of endometrial cancer despite the development of these novel agents. In the futu作者: 釘牢 時間: 2025-3-26 02:48
https://doi.org/10.1007/978-94-009-2717-9ny developed countries. Because rates of cervical cancer peak in older women, vaccination is expected to take some years to substantially reduce the overall rates of invasive cervical cancer, but in countries with high rates of vaccination coverage, cancer rates in younger women are expected to drop作者: 防銹 時間: 2025-3-26 05:32 作者: Esophagitis 時間: 2025-3-26 11:58 作者: 墻壁 時間: 2025-3-26 13:58 作者: 下級 時間: 2025-3-26 16:53
https://doi.org/10.1007/978-94-009-3081-0 for rare cancers, patient accrual to trials is frequently prolonged, there is no consensus about the most efficient clinical trial design methodology, and national regulatory requirements currently significantly impair the ability to conduct international trials. In this chapter, we discuss the pro作者: CREEK 時間: 2025-3-27 00:40
https://doi.org/10.1007/978-94-009-3081-0ed (stages III–IV) epithelial ovarian cancer (EOC). It is known that the quality of surgery is one of the most important factors affecting the outcome of women with advanced EOC. We have reviewed the European population-based literature, focusing especially on studies published in the last 10 years,作者: 笨拙的我 時間: 2025-3-27 01:24
https://doi.org/10.1007/978-94-009-3081-0ment for these patients has always been up-front surgery, with the aim of achieving complete macroscopic removal of tumor followed by chemotherapy. In 2010, the results from a large phase III randomized study performed by the EORTC suggested no difference in survival whether the chemotherapy was giv作者: 反省 時間: 2025-3-27 05:23 作者: 敲詐 時間: 2025-3-27 12:20
P. T. Tueller (Professor of Range Ecology)sease in a mean time of 15 month; only 30–40 % will survive 5 years. Several treatment strategies have been evaluated for prolonging the time free of disease and reducing the risk of death. Maintenance treatment, i.e., continuation of primary chemotherapy in patients without progression of the disea作者: concise 時間: 2025-3-27 14:27
P. T. Tueller (Professor of Range Ecology) and this has obvious prognostic importance. Tumor grade and histology are important when considering this pattern of spread, but the evidence for a survival benefit for lymphadenectomy is scarce, there has been no uniform agreement on the extent of lymphadenectomy, and long-term follow-up of patien作者: 領帶 時間: 2025-3-27 20:19
S. G. Leonard,R. L. Miles,P. T. Tuellerfication is the introduction of the sentinel node procedure for patients with early stage vulvar cancer. The introduction of the sentinel node procedure brought about a major decrease in treatment-related morbidity. However, some controversies remain and these will be discussed in this chapter.作者: 馬賽克 時間: 2025-3-27 23:08
J. T. A. Verhoeven,W. Koerselman,B. Beltmanity therapy that integrates (chemo)radiotherapy with less extensive surgery is well accepted in order to avoid stoma formation; however, the roles for adjuvant therapy after surgical management of both the primary and nodal disease are poorly defined. To avoid exenterative surgery in advanced diseas作者: Memorial 時間: 2025-3-28 05:48 作者: 催眠 時間: 2025-3-28 08:17 作者: intoxicate 時間: 2025-3-28 14:24
978-1-4471-7170-6Springer-Verlag London 2014作者: Albinism 時間: 2025-3-28 16:26
,Sentinel Node Biopsy—Does It Help in the Management of Vulvar Cancer?,fication is the introduction of the sentinel node procedure for patients with early stage vulvar cancer. The introduction of the sentinel node procedure brought about a major decrease in treatment-related morbidity. However, some controversies remain and these will be discussed in this chapter.作者: 消散 時間: 2025-3-28 20:55 作者: 減少 時間: 2025-3-28 23:28 作者: 自然環(huán)境 時間: 2025-3-29 05:30
Lymphadenectomy in Endometrial Cancer: The Controversy Rages Unabated, benefit. In this chapter, both sides of the debate are presented alongside a mutually agreeable trial design that has the potential to provide conclusive evidence, once and for all, for how early-stage endometrial cancer should be managed.作者: 豐滿中國 時間: 2025-3-29 09:57
What Is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer?,ghlighted. Risk-based treatment selection is emphasized, with the aim of sparing many patients with low-risk endometrial cancer unnecessary toxicities of adjuvant treatment. Ongoing and future research is mainly directed at investigating the role of adjuvant chemotherapy in patients with high-risk disease to improve outcomes.作者: panorama 時間: 2025-3-29 13:49 作者: ADORE 時間: 2025-3-29 17:06
What Is the Value of Lymphadenectomy in Early Ovarian Cancer?,urvival benefit for lymphadenectomy is scarce, there has been no uniform agreement on the extent of lymphadenectomy, and long-term follow-up of patients who have undergone systematic lymphadenectomy in this context is lacking including quality of life studies.作者: 偶像 時間: 2025-3-29 23:15 作者: 咆哮 時間: 2025-3-30 02:19 作者: 變化無常 時間: 2025-3-30 05:25
https://doi.org/10.1007/978-94-009-3081-0en following the surgery or as neoadjuvant treatment prior to surgery. This review will tease out the pros and cons of either management strategy based on the current evidence available and make recommendations for future research in the area.作者: ERUPT 時間: 2025-3-30 10:04
Book 2014selected either for their opposing views or for their ability to provide an opposite view or opinion to the other. The content will be evidence-based, illustrating contrasting evidence and scientific opinion in the literature. Each chapter will close on a summary indicating the direction of research needed to address the issues being discussed.作者: Hyaluronic-Acid 時間: 2025-3-30 15:09
The Classification of Vegetationaff expertise, and the management of treatment-related toxicity. Nonetheless, the improved survival justifies consideration of IP therapy in appropriate patients. Multiple approaches to decrease toxicity, improve tolerability, and indentify key treatment components are currently being evaluated.作者: Defense 時間: 2025-3-30 19:36 作者: 阻擋 時間: 2025-3-30 23:55
Does Intraperitoneal Therapy for Ovarian Cancer Have a Future?,aff expertise, and the management of treatment-related toxicity. Nonetheless, the improved survival justifies consideration of IP therapy in appropriate patients. Multiple approaches to decrease toxicity, improve tolerability, and indentify key treatment components are currently being evaluated.作者: 新娘 時間: 2025-3-31 01:46
Controversies in the Management of Advanced Vulvar Cancer,expert multidisciplinary opinion can guide management in order to obtain the therapeutic advantages of the modalities available and must be tailored to the patient- and tumor-related factors in each situation.作者: Gudgeon 時間: 2025-3-31 07:31
Controversies in the Treatment of Women with Early-Stage Epithelial Ovarian Cancer,e appropriate degree of surgical radicality, and need for lymphadenectomy, as well as the importance of fertility preservation in women with very early disease. We review the evidence for the need for adjuvant therapies and the optimum regimens particularly addressing the impact on younger women and long-term treatment sequelae in survivors.作者: Fracture 時間: 2025-3-31 10:17 作者: Irremediable 時間: 2025-3-31 16:01
When Should Surgery Be Performed for the First-Line Treatment of Advanced Ovarian Cancer?,en following the surgery or as neoadjuvant treatment prior to surgery. This review will tease out the pros and cons of either management strategy based on the current evidence available and make recommendations for future research in the area.作者: LUCY 時間: 2025-3-31 17:30 作者: 劇毒 時間: 2025-3-31 23:44 作者: prolate 時間: 2025-4-1 03:28 作者: abracadabra 時間: 2025-4-1 07:31
https://doi.org/10.1007/978-94-009-2717-9nhibitors. Chemotherapy continues to be the mainstay in the treatment of endometrial cancer despite the development of these novel agents. In the future, combining chemotherapy with targeted agents shows promise in improving progression-free survival in patients with endometrial cancer.作者: NAUT 時間: 2025-4-1 13:32 作者: Calibrate 時間: 2025-4-1 18:02
P. T. Tueller (Professor of Range Ecology)rsies regarding the impact of maintenance therapy for treating women with ovarian cancer exist. This chapter details the advantages and disadvantages of continuation medical treatment in newly diagnosed ovarian cancer after primary treatment based on the highest levels of evidence.
